Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism (IEMs), today announced that new clinical data from the Phase 1 study of AG-221, an orally available, selective, potent inhibitor of the mutated IDH2 protein, will be highlighted in an oral presentation at the 19th Congress of the European Hematology Association (EHA) taking place June 12 -15, 2014 in Milan, Italy.
"We look forward to sharing these new clinical data with the medical community during the late-breaker session at EHA," said David Schenkein, M.D., chief executive officer of Agios. "The data build upon the AG-221 preliminary results we presented last month at the American Association for Cancer Research (AACR) Annual Meeting, and include additional patients from existing and new dose cohorts."
Title: A Phase I Study of AG-221, a First in Class, Potent Inhibitor of the IDH2-Mutant Protein, in Patients with IDH2 Mutant Positive Advanced Hematologic Malignancies
Presentation time: Saturday, June 14 at 1:30 p.m. CEST
Session title: Late breaking1
Presenter: Stephane De Botton, M.D., Institut de Cancerologie Gustave Roussy, Villejuif, France
Abstract code: LB2434
Conference Call Information
Agios will host a conference call and webcast on Monday, June 16, 2014, at 8:30 a.m. EDT to review the clinical data presented at EHA from the ongoing Phase 1 study of AG-221.
Study focuses on COPD progression in younger populations